143 related articles for article (PubMed ID: 34405958)
1. Safety, satisfaction and cost savings of accelerated infusions of standard and intensified-dose infliximab for inflammatory bowel disease.
Crane H; Wu N; Chan P; Nguyen P; Williams AJ; Ng W; Connor SJ
Intern Med J; 2022 Dec; 52(12):2143-2149. PubMed ID: 34405958
[TBL] [Abstract][Full Text] [Related]
2. Accelerated Infliximab Infusion: Safety, Factors Predicting Adverse Events, Patients' Satisfaction and Cost Analysis. A Cohort Study in IBD Patients.
Mazzuoli S; Tricarico D; Demma F; Furneri G; Guglielmi FW
PLoS One; 2016; 11(11):e0166443. PubMed ID: 27851772
[TBL] [Abstract][Full Text] [Related]
3. Transitioning patients with inflammatory bowel disease from hospital-based to rapid home-based infliximab: A stepwise, safety and patient-orientated process towards sustainability.
Bohra A; Rizvi QA; Keung CYY; Vasudevan A; van Langenberg DR
World J Gastroenterol; 2020 Sep; 26(36):5437-5449. PubMed ID: 33024395
[TBL] [Abstract][Full Text] [Related]
4. Accelerated infliximab infusions for inflammatory bowel disease improve effectiveness.
McConnell J; Parvulescu-Codrea S; Behm B; Hill B; Dunkle E; Finke K; Snyder K; Tuskey A; Cox D; Woodward B
World J Gastrointest Pharmacol Ther; 2012 Oct; 3(5):74-82. PubMed ID: 23515325
[TBL] [Abstract][Full Text] [Related]
5. Safety and cost benefit of an accelerated infliximab infusion protocol in the treatment of ambulatory patients with inflammatory bowel diseases.
Saxena P; Chen G; Jideh B; Collins G; Leong RW
Expert Opin Biol Ther; 2014 Mar; 14(3):277-82. PubMed ID: 24359522
[TBL] [Abstract][Full Text] [Related]
6. Are accelerated infliximab infusions safe in patients with inflammatory bowel disease?
Bhat S; Sharma D; Doherty P; Tham TC; Caddy GR
Inflamm Bowel Dis; 2010 Nov; 16(11):1922-5. PubMed ID: 20848465
[TBL] [Abstract][Full Text] [Related]
7. The Tolerability and Efficacy of Rapid Infliximab Infusions in Patients with Inflammatory Bowel Disease.
Qazi T; Shah B; El-Dib M; Farraye FA
Dig Dis Sci; 2016 Feb; 61(2):589-96. PubMed ID: 26441281
[TBL] [Abstract][Full Text] [Related]
8. Rapid infusion of infliximab biosimilars and the incidence and severity of infusion-related reactions in patients with inflammatory bowel disease.
Rusch C; Wood M; Kennedy AG; Tompkins BJ; Frasca JD
J Clin Pharm Ther; 2022 Nov; 47(11):1851-1857. PubMed ID: 36134561
[TBL] [Abstract][Full Text] [Related]
9. Home Infliximab Infusions Are Associated With Suboptimal Outcomes Without Cost Savings in Inflammatory Bowel Diseases.
Giese-Kim N; Wu M; Dehghan M; Sceats LA; Park KT
Am J Gastroenterol; 2020 Oct; 115(10):1698-1706. PubMed ID: 32701731
[TBL] [Abstract][Full Text] [Related]
10. A quality improvement project reduces time spent at an inflammatory bowel disease infusion center with accelerated infliximab infusion protocol.
Ong WC; Lim MS; Chan E; Lim TCT; Lim TG; Chan W
JGH Open; 2022 Jul; 6(7):470-476. PubMed ID: 35822121
[TBL] [Abstract][Full Text] [Related]
11. Accelerated infliximab infusions are safe and well tolerated in patients with inflammatory bowel disease.
Clare DF; Alexander FC; Mike S; Dan G; Allan F; Lisa W; Peter HJ
Eur J Gastroenterol Hepatol; 2009 Jan; 21(1):71-5. PubMed ID: 19060632
[TBL] [Abstract][Full Text] [Related]
12. A nurse-led accelerated procedure for infliximab infusion is well tolerated and effective in patients with inflammatory bowel disease.
Michielan A; Martinato M; Favarin A; Zanotto V; Caccaro R; Caruso A; Sturniolo GC; D'Incà R
Dig Liver Dis; 2015 May; 47(5):372-7. PubMed ID: 25708258
[TBL] [Abstract][Full Text] [Related]
13. Infliximab administered with shortened infusion times in a specialized IBD infusion unit: a prospective cohort study.
Van Assche G; Vermeire S; Noman M; Amant C; Weyts E; Vleminckx A; Vermeyen MJ; Rutgeerts P
J Crohns Colitis; 2010 Sep; 4(3):329-33. PubMed ID: 21122522
[TBL] [Abstract][Full Text] [Related]
14. A home infliximab infusion program.
Condino AA; Fidanza S; Hoffenberg EJ
J Pediatr Gastroenterol Nutr; 2005 Jan; 40(1):67-9. PubMed ID: 15625429
[TBL] [Abstract][Full Text] [Related]
15. Safety of Accelerated Infliximab Infusions in Children With Inflammatory Bowel Disease: A Retrospective Cohort Study.
Jagt JZ; Galestin SE; Claesen J; Benninga MA; de Boer NKH; de Meij TGJ
J Pediatr Gastroenterol Nutr; 2023 Sep; 77(3):373-380. PubMed ID: 37319101
[TBL] [Abstract][Full Text] [Related]
16. Infliximab for the treatment of psoriasis in the U.K.: 9 years' experience of infusion reactions at a single centre.
Wee JS; Petrof G; Jackson K; Barker JN; Smith CH
Br J Dermatol; 2012 Aug; 167(2):411-6. PubMed ID: 22404545
[TBL] [Abstract][Full Text] [Related]
17. Accelerated Infliximab Infusion Safety and Tolerability Is Non-inferior to Standard Infusion Protocol in Inflammatory Bowel Disease Patients: A Randomized Controlled Study.
Abushamma S; Walker T; Garza K; Chen L; Nix D; Chen CH
Crohns Colitis 360; 2023 Jul; 5(3):otad022. PubMed ID: 37288326
[TBL] [Abstract][Full Text] [Related]
18. Tolerability of one hour 10mg/kg infliximab infusions in inflammatory bowel diseases: a prospective multicenter cohort study.
Babouri A; Roblin X; Filippi J; Hébuterne X; Bigard MA; Peyrin-Biroulet L
J Crohns Colitis; 2014 Feb; 8(2):161-5. PubMed ID: 23994253
[TBL] [Abstract][Full Text] [Related]
19. Meta-analysis: rapid infliximab infusions are safe.
Neef HC; Riebschleger MP; Adler J
Aliment Pharmacol Ther; 2013 Aug; 38(4):365-76. PubMed ID: 23815183
[TBL] [Abstract][Full Text] [Related]
20. Safety of Hydrocortisone Premedication Discontinuation in Patients with Inflammatory Bowel Disease on Maintenance Therapy with Infliximab: a Prospective Clinical and Pharmacological Study.
Tran-Minh ML; Gornet JM; Maillet M; Houze P; Simon M; McLellan P; Hassid D; Vivier-Chicoteau J; Baudry C; Hammoudi N; Allez M
J Crohns Colitis; 2021 May; 15(5):742-748. PubMed ID: 33205193
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
